ABOUT US Acerta Pharma serves as AstraZeneca’s “Hematologic Oncology Center of Excellence”. As such, it has the responsibility of developing both internally discovered compounds as well as AstraZeneca sourced compounds for hematological malignancies. The company began operations in 2013 with the vision of combining cutting edge science, unique covalent technology, and an experienced, dedicated team in order to deliver novel targeted therapies for patients with cancer. In February 2016, AstraZeneca made a multibillion-dollar investment in Acerta Pharma for 55% ownership, driven by the lead investigational Bruton tyrosine kinase (BTK) inhibitor, acalabrutinib and the opportunity to build out its hematology/oncology pipeline. (see Press Release – February 2, 2016). AstraZeneca holds the option to purchase the remainder of Acerta Pharma and complete a full acquisition. Acerta Pharma’s discovery and research teams, which focus on developing new molecular entities, are based in Oss, The Netherlands. The group there was responsible for the discovery of acalabrutinib. Our largest site, which includes clinical operations, medical science, regulatory, safety, compliance, biostatistics, medical affairs and US administration is located in South San Francisco, CA. The acalabrutinib program includes over 20 clinical trials for both monotherapy and in combination with other targeted molecules. Over 200 employees are engaged in the development of acalabrutinib and other pipeline compounds for hematologic malignancies. Plans to expand the oncology program include testing other targeted compounds in combination with acalabrutinib in a variety of blood based oncology indications. © 2018 Acerta PharmaAll rights reserved

BOARD OF DIRECTORS Pascal Soriot Executive Director and Chief Executive Officer – AstraZeneca plc Marc Dunoyer Executive Director and Chief Financial Officer – AstraZeneca plc Robert Schuller Chief Financial Officer – AstraZeneca Netherlands Tjeerd Barf Executive Vice President – Chemistry – AcertaPharma © 2018 Acerta PharmaAll rights reserved

LATE STAGE DEVELOPMENT Flavia Borellini, PhD Chief Executive Officer Iris Roth, PhD Vice President – Global Medicines Lead – Acalabrutinib Michele Fernandes, BSc (Hons), PMP Vice President – Business Operations and Alliance Management Davy Chiodin, PharmD Vice President – Regulatory Science and Quality Assurance Emily Roberts-Thomson, MMedSci Vice President – Clinical Operations Dr. Edwin J. Tucker BSc (Hons.), MB ChB, MRCP (UK), DPM, MBA Senior Vice President – Clinical Development and Medical Safety Naomi Hunder, MD Vice President – Medical Affairs and Strategic Collaborations Founders Corner Acerta Pharma thanks its cofounders for their efforts, sacrifices and dedication to bringing acalabrutinib to patients. Dr. Ahmed Hamdy: Medical Dr. Allard Kaptein: Discovery Dr. Raquel Izumi: Clinical Operations Dr. Tjeerd Barf: Chemistry Mr. Francisco Salva: Finance & Operations © 2018 Acerta PharmaAll rights reserved